samedan logo
home > pmps > autumn 2021 > the future of drug manufacturing innovation
Pharmaceutical Manufacturing and Packing Sourcer

The Future of Drug Manufacturing Innovation

PMPS: What are the main challenges facing tablet production today?

Korinde van den Heuvel: Despite tablets being the main mode of pharmaceutical delivery worldwide, there are major challenges in the way they are made and the way they are taken. Traditional facilities are not geared towards the smallscale production needed for clinical trials, orphan drugs, or the creation of designer tablets for personalised medicine. Taste, mouthfeel, or solubility can make tablets hard to take. Tablets also have a lack of dose flexibility. Smaller measurements are often delivered by breaking tablets into segments, which results in imprecise dosing.

Why should pharma companies consider 3D printed tablets?

From enabling personalised medicine to accelerating the drug development pathway, 3D printing offers huge potential to meet the above challenges. It offers opportunities in shape modifications, dose flexibility, solubility enhancement, and multiple pills with multiple active pharmaceutical ingredients (APIs). There is huge potential to deliver bespoke, small batches in the clinical trials market. When it comes to patient-centred medicine, 3D printed tablets, which can be created on demand in local healthcare settings could open up a new era of personalised medicines. Whatís more, the 3D printing of medications can potentially accelerate the scaling up of manufacturing.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Having joined DFE Pharma in April 2014, Korinde van den Heuvel is a Senior Product Developer who has worked on multiple oral solid dose (OSD) projects, as well as focusing on 3D printing of pharmaceutical tablets. Prior to working at DFE Pharma, Korinde worked in formulation development at Synthon for 10 years developing various generic and OSD forms, such as orally disintegrating, immediate release, and modified release tablets and capsules. Korinde holds a Masterís degree in Organic Chemistry from the Radboud University in Nijmegen, The Netherlands.

Print this page
Send to a friend
Privacy statement
News and Press Releases

Petrovax presents its products in Europe

Russian pharmaceutical company Petrovax is expanding its export portfolio and considering new markets for its pharmaceuticals and vaccines. At CPHI Worldwide 2021, an international pharmaceutical exhibition from 9th to11th November in Milan, Italy, Petrovax received over 70 offers from potential partners in Eastern Europe, the Middle East, and Latin America.
More info >>

White Papers

Running Smarter Trials With Data-Driven Monitoring


Clinical monitoring remains one of the most important and most costly activities in the clinical research paradigm.  Monitoring provides the operational transparency required by investigators, sponsors, and regulators to make informed decisions about site performance, patient safety, and overall study progress. Yet unlike many clinical trial activities, which have been steadily transformed by technology, the monitoring function itself has changed little.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement